亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer

医学 内科学 乳腺癌 安慰剂 二甲双胍 肿瘤科 癌症 妇科 胰岛素 病理 替代医学
作者
Pamela J. Goodwin,Bingshu E. Chen,Karen A. Gelmon,Timothy J. Whelan,Marguerite Ennis,Julie Lemieux,Jennifer A. Ligibel,Dawn L. Hershman,Ingrid A. Mayer,Timothy J. Hobday,Judith M. Bliss,Priya Rastogi,Manuela Rabaglio,Som D. Mukherjee,John R. Mackey,Vandana G. Abramson,Conrad D. Oja,Robert Wesolowski,Alastair M. Thompson,Daniel Rea
出处
期刊:JAMA [American Medical Association]
卷期号:327 (20): 1963-1963 被引量:148
标识
DOI:10.1001/jama.2022.6147
摘要

Importance

Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies.

Objective

To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes.

Design, Setting, and Participants

MA.32, a phase 3 randomized, placebo-controlled, double-blind trial, conducted in Canada, Switzerland, US, and UK, enrolled 3649 patients with high-risk nonmetastatic breast cancer receiving standard therapy between August 2010 and March 2013, with follow-up to October 2020.

Interventions

Patients were randomized (stratified for hormone receptor [estrogen receptor and/or progesterone receptor {ER/PgR}] status, positive vs negative; body mass index, ≤30 vs >30; human epidermal growth factor receptor 2 [ERBB2,formerlyHER2orHER2/neu], positive vs negative; and any vs no chemotherapy) to 850 mg of oral metformin twice a day (n = 1824) or oral placebo twice a day (n = 1825) for 5 years.

Main Outcomes and Measures

The primary outcome was invasive disease–free survival in hormone receptor–positive breast cancer. Of the 8 secondary outcomes, overall survival, distant relapse–free survival, and breast cancer–free interval were analyzed.

Results

Of the 3649 randomized patients (mean age, 52.4 years; 3643 women [99.8%]), all (100%) were included in analyses. After a second interim analysis, futility was declared for patients who were ER/PgR−, so the primary analysis was conducted for 2533 patients who were ER/PgR+. The median duration of follow-up in the ER/PgR+ group was 96.2 months (range, 0.2-121 months). Invasive disease–free survival events occurred in 465 patients who were ER/PgR+. The incidence rates for invasive disease–free survival events were 2.78 per 100 patient-years in the metformin group vs 2.74 per 100 patient-years in the placebo group (hazard ratio [HR], 1.01; 95% CI, 0.84-1.21;P = .93), and the incidence rates for death were 1.46 per 100 patient-years in the metformin group vs 1.32 per 100 patient-years in the placebo group (HR, 1.10; 95% CI, 0.86-1.41;P = .47). Among patients who were ER/PgR−, followed up for a median of 94.1 months, incidence of invasive disease–free survival events was 3.58 vs 3.60 per 100 patient-years, respectively (HR, 1.01; 95% CI, 0.79-1.30;P = .92). None of the 3 secondary outcomes analyzed in the ER/PgR+ group had statistically significant differences. Grade 3 nonhematological toxic events occurred more frequently in patients taking metformin than in patients taking placebo (21.5% vs 17.5%, respectively,P = .003). The most common grade 3 or higher adverse events in the metformin vs placebo groups were hypertension (2.4% vs 1.9%), irregular menses (1.5% vs 1.4%), and diarrhea (1.9% vs 7.0%).

Conclusions and Relevance

Among patients with high-risk operable breast cancer without diabetes, the addition of metformin vs placebo to standard breast cancer treatment did not significantly improve invasive disease–free survival.

Trial Registration

ClinicalTrials.gov Identifier: NCT01101438
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小泉完成签到 ,获得积分10
1秒前
星辰大海应助高兴的忆曼采纳,获得10
47秒前
英姑应助核桃采纳,获得10
1分钟前
科研通AI5应助核桃采纳,获得10
1分钟前
科研通AI5应助核桃采纳,获得10
1分钟前
可爱的函函应助核桃采纳,获得10
1分钟前
Liufgui应助核桃采纳,获得10
1分钟前
在水一方应助核桃采纳,获得10
1分钟前
隐形曼青应助科研通管家采纳,获得10
1分钟前
丘比特应助科研通管家采纳,获得10
1分钟前
爆米花应助科研通管家采纳,获得10
1分钟前
LONG完成签到 ,获得积分10
1分钟前
秋风今是完成签到 ,获得积分10
1分钟前
2分钟前
核桃发布了新的文献求助10
2分钟前
biubiubiu驳回了852应助
2分钟前
AUGKING27完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
无语的诗柳完成签到 ,获得积分10
3分钟前
nina完成签到 ,获得积分10
3分钟前
远山淡影_cy完成签到,获得积分20
3分钟前
康谨完成签到 ,获得积分10
3分钟前
blenx完成签到,获得积分10
3分钟前
3分钟前
小叶子完成签到 ,获得积分10
3分钟前
Liufgui应助徐悦月采纳,获得10
3分钟前
3分钟前
Dave完成签到,获得积分10
3分钟前
FashionBoy应助Dave采纳,获得10
4分钟前
4分钟前
4分钟前
4分钟前
顾矜应助Emon采纳,获得10
4分钟前
4分钟前
4分钟前
芝麻完成签到,获得积分10
4分钟前
5分钟前
Dave发布了新的文献求助10
5分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990045
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256334
捐赠科研通 3270943
什么是DOI,文献DOI怎么找? 1805146
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228